Tag Archive for: FUM

Futura Medical – MED3000 approved for Commercialisation in Saudi Arabia under the brand name Eroxon®

/in

Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), the pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology, today announces that its distribution partner Labatec Pharma (“Labatec”) has received regulatory approval for MED3000, Futura’s innovative topical, gel-based Erectile Dysfunction (“ED”) treatment, in the Kingdom of Saudi Arabia. Read more…

Read more

Futura Medical Full Year Results for the year ended 31 December 2022

/in

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, is pleased to announce its audited results for the year ended 31 December 2022. Read more…

Read more

Pre-launch of MED3000 Eroxon™ ahead of H1 2023 launch

/in

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, announces that its partner, Cooper Consumer Health (“Cooper”) has initiated pre-launch activities ahead of the launch of MED3000 (Eroxon™), Futura’s breakthrough, topical gel formulation for the treatment of erectile […]

Read more

Futura Medical provide update on a milestone year of regulatory and commercial progress for MED3000

/in

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, is pleased to provide an update on a pivotal year of regulatory progress and commercial activities for MED3000. Read more…

Read more

Futura Announces Collaboration with Cooper Consumer Health to Commercialise MED3000 in EEA, United Kingdom and Switzerland

/in

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces it has entered into an exclusive licensing agreement with Cooper Consumer Health  (“Cooper”), a leading European independent self-care organisation, for the rights to commercialise the […]

Read more